
|Articles|January 22, 2007
ASCO GI: Transplant Shows Best Survival for Local Liver Cancer Therapy
ORLANDO -- If all things were equal, a new liver would offer the best chance of long term survival for hepatocellular carcinoma -- but these patients make up a heterogeneous group.
Advertisement
ORLANDO, Jan. 22 -- If all things were equal, a new liver would offer the best chance of long term survival for hepatocellular carcinoma.
So said Roderich Schwarz, M.D., of the Cancer Institute of New Jersey in New Brunswick, who compared survival for three local treatment strategies -- transplant, surgical resection, and ablation.
After five years, the survival rate for transplant patients was 67%, versus 38% for those who had surgical resection and 19% for ablation procedures (P
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
The Future of PMOS Care: GLP-1 Therapy and Weight-Loss Caution
2
FDA Grants Breakthrough Therapy Designation to DT120 for Major Depressive Disorder
3
The PMOS Diagnostic Workup: Labs, Rule-Outs, and Timing Tips
4
Probiotic Use Surges as Fiber Intake Stagnates in US Adults, Young Adults
5


















































































































































